Advanced Enzyme Technologies Ltd

Advanced Enzyme Technologies Capital Structure Change

Advanced Enzyme Technologies announced an open market buyback of up to 13.94 lakh shares at a maximum price of ₹500 per share.

Execution

2026-08-14 to 2026-11-20

Advanced Enzyme Technologies Merger & Restructuring Worth ₹2 Cr

Advanced Enzyme Technologies is investing ₹2 Crore in its wholly-owned subsidiary, Advanced Nutrazyme Private Limited. This capital infusion supports the subsidiary's ongoing business operations.

Value

₹2.00 Cr

Execution

31-12-2027

Advanced Enzyme Technologies Merger & Restructuring Worth ₹7.98 Cr

Advanced Enzyme Technologies Limited will acquire the remaining 4.28% stake in JC Biotech Private Limited for ₹7.98 Crore, making it a wholly-owned subsidiary.

Value

₹7.98 Cr

Advanced Enzyme Technologies Capital Structure Change

Advanced Enzyme Technologies Limited's board approved a buyback of up to 1.39 million shares worth ₹69.7 Crore via the open market to optimize capital.

Value

₹69.70 Cr

Advanced Enzyme Technologies Investor Presentation: Key Takeaways

Advanced Enzyme reported Q1 FY27 revenue of ₹1,898 mn, up 2% YoY, despite a 10% EBITDA decline. Segment performance was mixed, with specialized manufacturing and bio-processing showing strong growth.

Advanced Enzyme Technologies Results Update

Advanced Enzyme Technologies announced its Q1 FY27 consolidated financial highlights. Consolidated revenue from operations stood at ₹189.8 Crore for the quarter.

Advanced Enzyme Technologies Q1 FY27 Results: Net Profit ₹38.6 Cr, Down 4.5% YoY

Advanced Enzyme Technologies Ltd reported revenue from operations of ₹189.8 Cr (+2.1% YoY) and net profit of ₹38.6 Cr (-4.5% YoY) for Q1 FY27.

Key figure

Net profit ₹38.6 Cr · -4.5% YoY